Novo Nordisk

Headlines · 4

1. 6d
   AI drug discovery hits a bottleneck as wet-lab work slows the pace

   An industry commentary argues that AI is already embedded in pharma R&D — literature review, molecule generation and clinical-trial management — but models trained only on public data cannot create a moat, so companies are shifting toward building their own “dry-wet” design-build-test-learn loops to accumulate proprietary data. It notes that Anthropic was reported to have set up a biological wet lab in the San Francisco Bay Area, that Eli Lilly's Lilly TuneLab signed GenScript, Twist Bioscience and Ginkgo Bioworks to supply wet-lab data, and that in the Novo Nordisk breach the leaked proprietary biological and chemical training data amounted to only about 407MB. Citing estimates compiled by Southwest Securities, the piece says AI can cut timelines by 70–90% in discovery, 50–80% in pre-clinical and 50–60% in clinical stages, while stressing that AI remains a hypothesis-generating assistant rather than a decision system, and that success still hinges on whether a target truly causes the disease.

   虎嗅 AI · 🔥 0
2. 7d
   Anthropic to spend $100M training 10,000 forward-deployed engineers

   Anthropic said it will invest $100 million in a program to train Frontier Deployed Engineers and launch a Claude Frontier Academy, with a goal of training 10,000 people by the end of 2027. Companies nominate engineers rather than individuals applying directly, and candidates must arrive with a defined Claude project; the first cohorts have started in New York and San Francisco — with reports also citing London — drawing participants from Accenture, Bain, Capgemini, Deloitte, McKinsey, Morgan Stanley, Novo Nordisk and Commonwealth Bank of Australia, among others. Participants first take several days of in-person training, practicing use-case selection and agent-system deployment in simulated enterprise settings, then pass a practical assessment before returning to their own companies for a 12-week residency with continued Anthropic mentoring and a final certification. Anthropic executives said strong candidates need familiarity with agentic AI systems, problem-solving and communication skills and solid engineering backgrounds, and singled out curiosity as a key trait, framing the effort as a bid to set a "gold standard" for AI skills training.

   IT之家 AI · 🔥 0
3. Oct 8
   Eli Lilly CEO: AI drug discovery still needs far more biology data

   In an interview on the Cheeky Pint podcast, Eli Lilly CEO David Ricks said the company's LillyPod biomedical supercomputer — 1,016 NVIDIA Blackwell Ultra GPUs on a DGX SuperPOD B300 architecture — is being used to train biomedical AI models for drug discovery and molecular design, and that Lilly and NVIDIA plan to invest up to $1 billion over five years in a joint AI innovation lab. Ricks estimated humans understand only 10–15% of biology and said coverage may need to exceed 50% before AI can reliably predict complex biological systems, proposing round-the-clock robotic labs to generate the missing data. He also said China now accounts for roughly 30% of global drug development pipelines, and argued for about 12 years of clinical data exclusivity on top of patents for drugs that complete Phase III trials.

   MIT科技评论中文 · 🔥 0
4. Oct 8
   Anthropic launches Claude Frontier Academy with $100M to train 10,000 engineers

   Anthropic announced Claude Frontier Academy, a $100 million program aiming to train 10,000 forward-deployed engineers by the end of 2027, with the first cohort drawn from Accenture, Bain, Deloitte, McKinsey, Morgan Stanley and Novo Nordisk, among others. Training combines a four-day in-person bootcamp with a 12-week real project inside the participant's own organization, leading to Claude Resident Engineer and, after a second assessment, Claude Frontier Deployed Engineer credentials, with the first final certifications expected in early 2027. Enrollment is currently by company nomination through Anthropic's account or partner teams.

   36氪 人工智能 · 🔥 0

Experience and discussion from the community

Share my Novo Nordisk experienceAsk about Novo Nordisk